Starpharma Holdings Ltd. (SPHRY)
5.05
-0.80
(-13.68%)
USD |
OTCM |
Oct 02, 16:00
Starpharma Holdings Max Drawdown (5Y) : 97.54% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 97.54% |
| August 31, 2026 | 97.54% |
| July 31, 2026 | 97.54% |
| June 30, 2026 | 97.54% |
| May 31, 2026 | 97.54% |
| April 30, 2026 | 97.54% |
| March 31, 2026 | 97.54% |
| February 28, 2026 | 97.54% |
| January 31, 2026 | 97.54% |
| December 31, 2025 | 97.54% |
| November 30, 2025 | 97.54% |
| October 31, 2025 | 97.54% |
| September 30, 2025 | 97.54% |
| August 31, 2025 | 97.54% |
| July 31, 2025 | 97.54% |
| June 30, 2025 | 97.54% |
| May 31, 2025 | 97.54% |
| April 30, 2025 | 97.27% |
| March 31, 2025 | 97.27% |
| February 28, 2025 | 97.27% |
| January 31, 2025 | 97.27% |
| December 31, 2024 | 97.27% |
| November 30, 2024 | 97.27% |
| October 31, 2024 | 97.27% |
| September 30, 2024 | 97.27% |
| Date | Value |
|---|---|
| August 31, 2024 | 97.27% |
| July 31, 2024 | 97.04% |
| June 30, 2024 | 96.69% |
| May 31, 2024 | 96.55% |
| April 30, 2024 | 95.95% |
| March 31, 2024 | 95.95% |
| February 29, 2024 | 95.95% |
| January 31, 2024 | 95.95% |
| December 31, 2023 | 95.95% |
| November 30, 2023 | 95.95% |
| October 31, 2023 | 95.95% |
| September 30, 2023 | 95.38% |
| August 31, 2023 | 95.11% |
| July 31, 2023 | 91.70% |
| June 30, 2023 | 89.96% |
| May 31, 2023 | 86.39% |
| April 30, 2023 | 84.49% |
| March 31, 2023 | 83.92% |
| February 28, 2023 | 83.65% |
| January 31, 2023 | 83.65% |
| December 31, 2022 | 83.65% |
| November 30, 2022 | 83.65% |
| October 31, 2022 | 83.55% |
| September 30, 2022 | 80.24% |
| August 31, 2022 | 77.92% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Percheron Therapeutics Ltd. | 99.63% |
| Neuren Pharmaceuticals Ltd. | 61.55% |
| Mayne Pharma Group Ltd. | 89.56% |
| Acrux Ltd. | 99.51% |
| Zelira Therapeutics Ltd. | 99.60% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -25.56 |
| Beta (5Y) | 1.309 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 82.37% |
| Historical Sharpe Ratio (5Y) | -0.1513 |
| Historical Sortino (5Y) | -0.3711 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 22.61% |